you are here:

Unichem Laboratories Ltd.

BSE: 506690 | NSE: UNICHEMLAB |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE351A01035 | SECTOR: Pharmaceuticals

BSE Live

Jul 29, 16:00
333.60 1.20 (0.36%)
Volume
AVERAGE VOLUME
5-Day
3,594
10-Day
6,179
30-Day
6,148
4,141
  • Prev. Close

    332.40

  • Open Price

    335.95

  • Bid Price (Qty.)

    332.60 (100)

  • Offer Price (Qty.)

    339.65 (25)

NSE Live

Jul 29, 16:02
332.80 0.45 (0.14%)
Volume
AVERAGE VOLUME
5-Day
51,261
10-Day
59,412
30-Day
50,602
45,802
  • Prev. Close

    332.35

  • Open Price

    334.00

  • Bid Price (Qty.)

    332.80 (556)

  • Offer Price (Qty.)

    0.00 (0)

Annual Report

For Year :
2019 2017 2016 2015 2014 2013 2011 2010 2009

Chairman's Speech

Last financial year was a good year for the Company in terms of turnover, profit and dividend. The Company earned PBIDTA of Rs. 179.45 Crores as against Rs. 154.15 Crores earned in the previous financial year despite difficult environment throughout the world. Though the turnover grew modestly by 5.39%, at Rs. 683.84 Crores, the Company earned decent profits which enabled it to declare two interim dividends aggregating to Rs. 10/- per equity share of Rs. 5/- [200%]. This is the biggest payout in the history of Unichem. Over 73% of our turnover is contributed by the Domestic formulation market where Unichem enjoys an enviable reputation built over six decades. Therefore, one of our key strategies is to consolidate our presence in the domestic market. We can achieve this through expanding our product basket covering more therapeutic segments, by deeper market penetration and expanding our reach to larger number of customers. The growth potential for Unichem is enormous considering the opportunity that exists in unrepresented therapeutic segments. Towards this end, we have aligned product portfolios of our domestic formulation business into 8 therapy based Divisions which includes the two Divisions called Integra and Unikare launched in the last two years. All these Divisions are doing well and its products are well received by the medical fraternity. We also intend to add 500 more field personnel across these Divisions in order to cover more medical professionals. We had launched 19 new products last Financial Year and we intend to launch many more in the current Financial Year which will expand our product basket across various therapies. We have been continuously upgrading and expanding our manufacturing and research facilities at multiple locations to enrich our own product basket, to make products available in the regulated generic markets of the world and also to support our strategic positioning for contract manufacturing and research. The progress in this respect is heartening. Our manufacturing locations at Goa, Roha and Pithampur are certified by USFDA. Out of these, Goa and Roha Plants were already approved earlier by USFDA and received re- certifications. Our Sikkim Plant is commissioned and production has started in this formulation plant. Plant No. 1 at Baddi is undergoing extensive modernization programme and this plant is expected to be ready for commercial production by October this year. Construction work for a formulation plant at SEZ, Pithampur, Madhya Pradesh is under progress and substantial construction work will be completed by the end of the current financial year. We have made significant investments in manufacturing and research facilities over the last few years catering to both domestic and international market which makes Unichem the ideal partner for collaborative business. To make this happen, we have started leveraging our manufacturing, development and marketing strengths with key business partners and we are sure that these efforts will add long term value to our stakeholders. With regard to the global markets, our UK Subsidiary, Niche Generics Limited has commissioned its new packing facility in Baldoyle, Ireland and this will reduce manufacturing costs and release much needed funds for developing the markets. Already, development support is provided by our labs and plants in India. Similarly, regular shipments to US and South America have commenced. With more product approvals in the pipeline, the foundation for substantial ramp up in sales has been laid. Our focus on the API business continues to form an integral part of our strategy to drive the growth of the Company both in APIs and in Dosage Form business. Even though our exports of APIs did suffer during the year due to the adverse effect of the global meltdown particularly in Europe, we were able to gain the momentum by the end of the year. We are confident of maintaining this surge during the next year and beyond. With our Dosage Form business in the US slated for a take off, the focus on our API business of support to the international business has started giving the desired results. In addition, new initiatives to expand our API business to a number of new geographical markets are in the pipeline which should drive growth in the coming years. Our customers, business associates and shareholders have reposed their faith in us. I am grateful to them for their continued confidence in the management. I would also like to record my sincere appreciation for the commitment of our employees for their contribution. I firmly believe that having made substantial investments in plants, products and market development and with the large opportunities in front of us, we will continue to create superior value for all our stakeholders. Warm Regards Dr. Prakash A. Mody Chairman & Managing Director